TABLE 2.
Applications of albumin-based hydrogels in cancer therapy (Excerpt).
| Citations | Types of albumin | Drug | Cancer or tumor cells |
|---|---|---|---|
| Zhao et al. (2019) | BSA | NA | HepG2 |
| Amatya et al. (2021) | BSA | Ag NP | Skin cancer |
| Chen et al. (2021) | BSA | DOX | 4T1 |
| Lee et al. (2022) | BSA | PTX | 4T1 |
| Lin et al. (2017) | BSA | PTX | Human brain tumor cells |
| Qi et al. (2022) | BSA | Photothermal-photodynamic therapy | Breast cancer |
| Lee et al. (2018) | BSA | DOX | Hypoxic breast cancer |
| Liu et al. (2018) | BSA | I131 | Mouse lung cancer cells |
| Nassar et al. (2019) | BSA | DOX | HepG2 |
| Shen et al. (2018) | BSA | DOX | Drug-resistant breast cancer |
| Upadhyay et al. (2018) | BSA | DOX | MCF-7, HeLa, MDA-MB-231 |
| Kim et al. (2015) | HSA | TRAIL | MIA PaCa-2 |
| Lee et al. (2020) | HSA | Indocyanine green | Precision cancer surgery |
| Yamada and Schneider (2016) | BSA | DOX | A549 |
| Lee et al. (2019) | OVA | Anti-tumor vaccines | lymphoma |
| Li et al. (2022) | BSA | PQ912 | Inhibiting local tumor recurrence and distal metastasis |
| Nandi et al. (2020) | BSA | DOX | A2780, MCF-7, MDA-MB-231, Hela |
| Noteborn et al. (2017) | HSA | DOX | MCF-7 |
| Yan et al. (2022) | BSA | CDDP, BSO, GOx | A549 and 4T1, cancer combination therapy |
| Mantooth et al. (2021) | BSA | Immune checkpoint inhibitors | MC38 |
| Qian et al. (2017) | Unclear | PTX | Tumor-regional chemotherapy |
| Yan et al. (2022) | BSA | Cisplatin | A549 and 4T1 |